Molecular Cancer Therapeutics

Table of Contents

American Association for Cancer Research

March 2014 • Volume 13 • Number 3

Table of Contents

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

TOOLS AND TECHNOLOGIES

LETTERS TO THE EDITOR

ABOUT THE COVER

STAT3 and NF-κB signaling pathways are often simultaneously activated in neoplastic cells and play important roles in tumorigenesis and drug sensitivity. TPCA-1, a previously found antagonist of IKKs, blocks STAT3 anchoring to upstream tyrosine kinase and inhibits STAT3 activation induced by cytokines and c-Src. Molecular modeling indicates that TPCA-1 is well docked into SH2 domain of STAT3 and formed hydrogen bond with Glu594. As a direct inhibitor of STAT3 and IKKs, TPCA-1 inhibits growth of non–small cell lung cancer (NSCLC) with EGFR mutation and potentiates the antitumor effect of gefitinib. For details, see article by Nan and colleagues on page 617.



Molecular Cancer Therapeutics

13 (3)

Mol Cancer Ther 2014;13:555-764.